Feasibility of Quantitative Magnetic Resonance Fingerprinting in Ovarian Tumours for T1and T2Mapping

The authors acknowledge research support from the National Institute of Health Research Cambridge Biomedical Research Centre, GlaxoSmithKline.Cancer Research UK (CRUK), the CRUK Cambridge Centre, Medical Research Council, CRUK/Engineering and Physical Sciences Research Council Imaging Centre in Cambridge and Manchester, Addenbrooke's Charitable Trust, and the Cambridge Experimental Cancer Medicine Centre.